Cabozantinib is a new biological treatment called a tyrosine kinase inhibitor or TKI. It stops signals that cancer cells use to divide and grow. It is currently being considered as a treatment option for patients who fail primary treatment with sorafenib.
Cabozantinib for Hepatocellular Carcinoma
![featured image](https://www.io.nihr.ac.uk/wp-content/uploads/2022/01/Patients-Public_Motifs_Conduction-broadcasting_RGB-scaled_edit1233.jpg)
Interventions:
Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184)
Indications:
Hepatocellular carcinoma (HCC)
Therapeutic Areas:
Gastrointestinal Cancer
Year:
2017